Tanya Barauskas Dorff, M.D.
Dr. Dorff graduated summa cum laude from University of Houston before attending the UCLA School of Medicine. There, she was inducted into the prestigious Alpha Omega Alpha honors society. She subsequently completed her internal medicine residency at Mount Sinai Hospital in New York, and finished subspecialty training in hematology and oncology at Los Angeles County+USC Medical Center.
Dr. Dorff was on the faculty at USC for nearly 10 years, eventually amassing over 75 publications in top-tier journals, including Cancer, Lancet Oncology and Journal of Clinical Oncology. She has been invited to speak at multiple national and international meetings, and serves on the National Comprehensive Cancer Network Prostate Cancer Guidelines Committee and the co-chair for prostate cancer in the SWOG genitourinary committee.
Dr. Dorff’s research interests in prostate cancer are wide-ranging. In the area of clinical trials, she is heavily involved in the design and conduct of trials with immunotherapy and exploring treatment combinations. She has also worked on trials examining lifestyle (supplements, exercise) and treatment side effects (cognitive function). Recently she was awarded a Prostate Cancer Foundation/Pfizer grant to study talazoparib specifically in an ethnically diverse population, working together with Zijie (ZJ) Sun, M.D., Ph.D., and others.
Dr. Dorff leads City of Hope’s joint effort with the Prostate Cancer Foundation to develop novel immune-based strategies for prostate cancer. Specifically, she leads an effort to develop chimeric antigen receptor (CAR) T cells – cells that are primed to target prostate cancer tissue. These strategies have been transformative in certain blood-based cancers. She is also engaging with TGen scientists to study ctDNA as a biomarker of minimal residual disease and the impact of the microbiome on treatment outcomes.
Dr. Dorff has assumed control of one of the largest clinical trial portfolios in genitourinary cancers, and treats patients with all types of genitourinary cancers, including testicular and penile cancer.
2003-2013, Internal Medicine, American Board of Internal Medicine
2006-present, Medical Oncology, American Board of Internal Medicine
2000, M.D., AOA, UCLA School of Medicine, Los Angeles, CA
1995, B.S., Biology, summa cum laude, University of Houston – Honors College, Houston, TX
2003-2006, Hematology & Medical Oncology, LAC+USC Medical Center, Los Angeles, CA
2001-2003, Internal Medicine, Mount Sinai Hospital, New York, NY
2000-2001, Internal Medicine, Mount Sinai Hospital, New York, NY
2023-present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2017-2023, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2017, Associate Professor of Clinical Medicine, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA
2008-2017, Assistant Professor of Clinical Medicine, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA
2008-2017, Faculty, Department of Medicine, USC+LAC Medical Center, Los Angeles, CA
2006-2008, Faculty - Voluntary, Department of Medicine, USC+LAC Medical Center, Los Angeles, CA
2021, Top Women in Medicine
2021, Southern California Super Doctors
2019, Southern California Top Doctors
2019, Top Doctor, Oncology, Los Angeles Business Journal
2018, LA Business Journal Top Doctors
2018, Exceptional Women in Medicine Award
2017, Super Doctors, Los Angeles
2016, Mentorship Award – Required Scholarly Project – Keck School of Medicine of USC
2014, Faculty Teaching Award, Oncology Fellowship, Keck School of Medicine of USC
2012 and 2014, “Top Doctor” Pasadena Magazine
2010, AUA Western Section Best Poster – 3rd place
2010, Faculty Teaching Award
2005, Fellowship Teaching Award
2000, Alpha Omega Alpha, Medical Honors Society
2000, AMWA Janet M. Glasgow Memorial Achievement Citation
2000, ACP/ASIM James R. Klinenberg Certificate of Merit
1992, National Merit Scholar
European Society for Medical Oncology
NRG Oncology
Society for Immunotherapy of Cancer
2016-present, Bladder Cancer Advocacy Network
2015-present, Academic and Community Cancer Research United, (co-leader GU group)
2015-present, Kidney Cancer Association
2009-present, Southwest Oncology Group
2004-present, American Society of Clinical Oncology
- Kasparian S, Wei O, Tsai N-C, Palmer J, Pal S, Lyou Y, Dorff T. A practical guide to relugolix: early experience with oral androgen deprivation therapy. Oncologist 2023 Aug 3;28(8):699-705
- Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, et al. EphrinB4 inhibition and pembrolizumab in metastatic urothelial carcinoma. J Clin Oncol 2023; 41:640-50.
- Saad F, deBono J, Barthelemy P, Dorff T, Mehra N, et al. Patient-reported outcomes in men with metastatic castration-resistant prostate cancer harboring DNA damage response alterations treated with Talazoparib: results from TALAPRO1. Eur Urol 2023; 83:352-60.
- Dorff T, Hirasawa Y, Acoba J, pagano I, Tamura D, Pal S, et al. Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. J IMmunother Cancer 2021; 9:e002931
- Dorff TB, Stein C, Kortylewski M, Posadas E, Synold T, Quinn D. Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2020 May 5. doi: 10.1089/cbr.2019.3397. Online ahead of print. PMID: 32366119
- Ballas L, Wei O, Daneshmand S, Schuckman A, Djaladat H, Aron M, D' Souza A, Quinn D, Dorff TB. Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature Clin Genitourin Cancer. 2020 Aug;18(4):e473-e477. doi: 10.1016/j.clgc.2019.12.016. Epub 2020 Jan 7.Clin Genitourin Cancer. 2020. PMID: 32044240
- Kim DJ, Otap D, Ruel N, Gupta N, Khan N, Dorff TB. NCI-Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center. J Clin Med 2020 Jun 24;9(6):1970. doi: 10.3390/jcm9061970. PMID: 32599694 PMCID: PMC7355880
- Dorff T, Lyou Y, Stein C. Defining Value in Metastatic Prostate Cancer: What Is the Cost of Living Longer and Better? JCO Oncol Pract. 2020 Feb;16(2):53-54. doi: 10.1200/JOP.19.00632. Epub 2020 Jan 21. PMID: 32045557
- Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 Aug;17(4):241-247.e1. doi: 10.1016/j.clgc.2019.02.010. Epub 2019 Mar 19. PMID:31227432
- Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. Am Soc Clin Oncol EducBook. 2019 Jan;39:321-330. doi: 10.1200/EDBK_239187. Epub 2019 May 17. PMID: 31099673